The aim of this study was to describe the distribution of CD4+ T cell count (CD4) of HIV-1 infected pregnant women diagnosed during prenatal counseling and testing (VCT), in Abidjan, Côte CD4. The overall uptake of the intervention (31.9%) was independent of the immune status.
Introduction
Maternal CD4+ T cell count (CD4) is strongly associated with HIV disease progression and is a strong predictor of mother-to-child transmission of HIV-1 (MTCT) and its prevention (PMTCT) with antiretrovirals 1, 2 .Yet, given the low uptake of PMTCT interventions in African settings, generally around 20% 1, 3 , the CD4 distribution among the overall population of HIV-infected pregnant women is still unknown. Our hypothesis in Abidjan, Côte d'Ivoire, was that women less advanced in HIV disease felt no interest in receiving PMTCT interventions and self-excluded themselves during antenatal follow-up. The stigmatization towards HIV-infected patients and the inappropriate attitude of some health workers described in this population could lead to this selfexclusion 4, 5 . The aim of this study was to describe the CD4 distribution in all women diagnosed antenatally as HIV-infected and to study the relation between immune status and the uptake of a PMTCT antiretroviral-based intervention. 
Population and methods

Since
Discussion and conclusion
To our knowledge, this study is the first to describe the immune status of all HIV+ women diagnosed antenatally in an African setting of high HIV-1 prevalence in relation to their uptake of a PMTCT intervention. The CD4 count was similar in HIV+ women who did not return for their test result and those who were informed their sero-status. No difference was also found in HIV+ infected pregnant women who did not accept the PMTCT antiretroviral prophylaxis and those who received the PMTCT package. Thus, in our study, the low uptake of the Ditrame Plus program cannot be explained by the self-exclusion of pregnant women in relation with advanced HIV disease. We did not use any clinical criteria such as the AIDS stage to perform these comparisons as it would grossly underestimate the proportion of women with advanced HIV disease. However, in our population stigma could well be the main factor limiting the uptake of the PMTCT program.
Population-specific research must be required to understand the different factors influencing the low uptake of the PMTCT interventions in sub-Saharan Africa. CD4 prevalence surveys might be helpful to adjust PMTCT antiretroviral strategies to women needs 1 . IQR: Interquartile range, SD: Standard deviation, DP: Ditrame Plus Project, ARVs: antiretroviral prophylaxis regimen (Zidovudine + Nevirapine), PMTCT: prevention of mother to child transmission of HIV.
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